SCHEMBL280369

SCHEMBL280369

Cc1ccc(C(=O)CS(=O)(=O)c2ccncc2)o1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 1/20 0.49
ALDH1A1 P00352 4/20 0.41
KDM4E B2RXH2 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
HSD17B10 Q99714 1/20 0.41
HSD11B1 P28845 2/20 0.41
KMT2A Q03164 2/20 0.40
RECQL P46063 2/20 0.40
NPC1 O15118 1/20 0.40
HPGD P15428 2/20 0.39
TSHR P16473 1/20 0.39
POLB P06746 2/20 0.38
MAPT P10636 1/20 0.38
MEN1 O00255 1/20 0.38
CYP1A2 P05177 1/20 0.37
CYP2C19 P33261 1/20 0.37
KLK7 P49862 1/20 0.37
CA12 O43570 1/20 0.37
CA9 Q16790 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3063764 0.76 HTT (0.55) HTTALDH1A1KDM4ESMN1; SMN2NPSR1
SCHEMBL279741 0.71 HSD11B1 (0.49) ALDH1A1HSD11B1KMT2ARECQLNPC1
SCHEMBL279927 0.71 HTT (0.49) HTTALDH1A1KDM4ESMN1; SMN2NPSR1
SCHEMBL15979714 0.69 HPGD (0.53) HTTALDH1A1SMN1; SMN2HPGDTSHR
SCHEMBL953093 0.69 HPGD (0.53) HTTALDH1A1SMN1; SMN2NPC1HPGD
SCHEMBL279925 0.69 KMT2A (0.45) ALDH1A1HSD11B1KMT2ARECQLNPC1
SCHEMBL3061913 0.68 HTT (0.57) HTTALDH1A1KDM4ESMN1; SMN2NPSR1
SCHEMBL4531583 0.68 HPGD (0.52) HTTALDH1A1KDM4ESMN1; SMN2NPC1
SCHEMBL128021 0.67 HPGD (0.50) HTTALDH1A1SMN1; SMN2NPC1HPGD
SCHEMBL9466217 0.67 HPGD (0.55) HTTALDH1A1SMN1; SMN2HSD17B10HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8134013-B2 Amide compound and thrombopoietin receptor activator NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2012-03-13 US disclosed
US-8134013-B2 Amide compound and thrombopoietin receptor activator NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2012-03-13 US disclosed
US-20090131659-A1 AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2009-05-21 US disclosed
US-20090131659-A1 AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2009-05-21 US disclosed
EP-1845090-A1 AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR Nissan Chemical Industries, Ltd. (JP) 2007-10-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090131659-A1 AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR TEK, PTAFR, MPL HTT 1630/4885ALDH1A1 2047/4885KDM4E 4435/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.